Literature DB >> 8228372

Degradation of human IgA by Entamoeba histolytica.

B L Kelsall1, J I Ravdin.   

Abstract

To determine whether the virulent enteric pathogen Entamoeba histolytica degrades human IgA molecules, serum and secretory IgA was exposed to viable axenic trophozoites (strain HM1:IMSS), a parasite sonicate, and medium conditioned by incubation with live trophozoites. IgA was completely degraded under all conditions, proteinase activity was maximal at a neutral pH, and there was a four- to eightfold enrichment of amebic IgA proteolytic activity in a soluble fraction of amebic sonicate. Degradation of serum IgA by amebic sonicate was completely inhibited by the cysteine proteinase inhibitors trans-epoxysuccinyl-L-leucyl-amino(4-guanidino)butane (E-64, 100 microM) and benzyloxycarbonyl-phenyl-alanyl-alanyl-fluoromethyl (Z-Phe-Ala-CH2F, 12.5 microM). Secretion of degradative activity, the optimal pH, and the inhibition by E-64 and Z-Phe-Ala-CH2F indicates that cysteine proteinase activity is predominantly responsible for the degradation of human IgA by E. histolytica.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8228372     DOI: 10.1093/infdis/168.5.1319

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  19 in total

1.  Degradation of human secretory immunoglobulin A by Blastocystis.

Authors:  Manoj K Puthia; Aparna Vaithilingam; Jia Lu; Kevin S W Tan
Journal:  Parasitol Res       Date:  2005-09-07       Impact factor: 2.289

2.  Intestinal invasion by Entamoeba histolytica.

Authors:  Shahram Solaymani-Mohammadi; William A Petri
Journal:  Subcell Biochem       Date:  2008

3.  Degradations of human immunoglobulins and hemoglobin by a 60 kDa cysteine proteinase of Trichomonas vaginalis.

Authors:  D Y Min; K H Hyun; J S Ryu; M H Ahn; M H Cho
Journal:  Korean J Parasitol       Date:  1998-12       Impact factor: 1.341

Review 4.  Progress towards development of a vaccine for amebiasis.

Authors:  S L Stanley
Journal:  Clin Microbiol Rev       Date:  1997-10       Impact factor: 26.132

5.  Immunization of rats with the 260-kilodalton Entamoeba histolytica galactose-inhibitable lectin elicits an intestinal secretory immunoglobulin A response that has in vitro adherence-inhibitory activity.

Authors:  B L Kelsall; J I Ravdin
Journal:  Infect Immun       Date:  1995-02       Impact factor: 3.441

6.  A novel Entamoeba histolytica cysteine proteinase, EhCP4, is key for invasive amebiasis and a therapeutic target.

Authors:  Chen He; George P Nora; Eric L Schneider; Iain D Kerr; Elizabeth Hansell; Ken Hirata; David Gonzalez; Mohammed Sajid; Sarah E Boyd; Petr Hruz; Eduardo R Cobo; Christine Le; Wei-Ting Liu; Lars Eckmann; Pieter C Dorrestein; Eric R Houpt; Linda S Brinen; Charles S Craik; William R Roush; James McKerrow; Sharon L Reed
Journal:  J Biol Chem       Date:  2010-04-08       Impact factor: 5.157

7.  Analysis of human immunoglobulin-degrading cysteine proteinases of Trichomonas vaginalis.

Authors:  D Provenzano; J F Alderete
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

Review 8.  Host-pathogen interaction in amebiasis and progress in vaccine development.

Authors:  C D Huston; W A Petri
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-09       Impact factor: 3.267

9.  Use of recombinant Entamoeba histolytica cysteine proteinase 1 to identify a potent inhibitor of amebic invasion in a human colonic model.

Authors:  Samuel G Meléndez-López; Scott Herdman; Ken Hirata; Min-Ho Choi; Youngchool Choe; Charles Craik; Conor R Caffrey; Elisabeth Hansell; Bibiana Chávez-Munguía; Yen Ting Chen; William R Roush; James McKerrow; Lars Eckmann; Jianhua Guo; Samuel L Stanley; Sharon L Reed
Journal:  Eukaryot Cell       Date:  2007-05-18

10.  Intranasal immunization with Gal-inhibitable lectin plus an adjuvant of CpG oligodeoxynucleotides protects against Entamoeba histolytica challenge.

Authors:  Catherine P A Ivory; Kris Chadee
Journal:  Infect Immun       Date:  2007-07-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.